ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers
November 15, 2022 08:32 ET
|
ExCellThera
MONTREAL, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today the completion of patient enrollment in its...
Global Leukapheresis Market Report 2022: Increased Demand for Leukopaks in Clinical Research Driving Growth
October 25, 2022 06:28 ET
|
Research and Markets
Dublin, Oct. 25, 2022 (GLOBE NEWSWIRE) -- The "Leukapheresis Market by Product (Devices, Filters, Membrane Separators), Leukopak (Mobilized, Non-Mobilized), Indication (ALL, NHL, Multiple Myeloma),...
T-Cell Therapy Market Size to Hit $21+ Billion with Booming CAGR Value of 20.7% by 2028 | The Insight Partners
October 20, 2022 09:22 ET
|
The Insight Partners
New York, Oct. 20, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners latest study on "T-cell Therapy Market Size, Share, Trends, Growth Strategy and Forecast to 2028 – COVID-19 Impact and...
Oncolyze, a Company Aiming to Treat Cancer by Exploding Cancer Cells, is Now Accepting Investments. Own a Piece in the Future of Cancer Treatment.
August 23, 2022 12:00 ET
|
Oncolyze Inc
NEW YORK, Aug. 23, 2022 (GLOBE NEWSWIRE) -- After successfully completing in vitro and in vivo (mice) experiments, which support the notion that its lead drug candidate OM-301 breaks down cancer...
Doxorubicin Market Revenue to Cross $1,983.40 million by 2028 to Rise at a Stellar CAGR of 6.1% by 2028 | Exclusive Research by The Insight Partners
July 12, 2022 10:54 ET
|
The Insight Partners
New York, July 12, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Doxorubicin Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Drug Formulation,...
UFCW Canada lifetime fundraising for Leukemia & Lymphoma Society of Canada tops $49 million thanks to $1.86 million campaign in 2021-2022
June 17, 2022 13:22 ET
|
UFCW Canada
TORONTO, June 17, 2022 (GLOBE NEWSWIRE) -- Another year of pandemic restrictions presented unique challenges for UFCW Canada’s fundraising efforts on behalf of the Leukemia & Lymphoma Society...
Protein Kinase Inhibitors in Oncology Analysis Service 2022: Must have Handbook for Any Business Developer, BI/CI Operative or Clinical Developer
June 15, 2022 07:58 ET
|
Research and Markets
Dublin, June 15, 2022 (GLOBE NEWSWIRE) -- The "Protein Kinase Inhibitors in Oncology: Analytical Tool" report has been added to ResearchAndMarkets.com's offering.Protein Kinase Inhibitors in...
Global Bruton Tyrosine Kinase (BTK) Inhibitors Market Size to Expand Significantly USD 4476.99 Million By 2030
May 11, 2022 16:00 ET
|
Fior Markets
Newark, NJ, May 11, 2022 (GLOBE NEWSWIRE) -- As per the report published by MRInsights.biz, the global Bruton tyrosine kinase (BTK) inhibitors market is expected to grow from USD 2,695.35 million in...
Oncolyze Announces FDA Orphan Drug Designation for OM-301 for the Treatment of Acute Myeloid Leukemia
January 05, 2022 09:00 ET
|
Oncolyze Inc
NEW YORK, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Oncolyze, Inc, a biotech developing a disruptive technology for the treatment of cancer, today announced that the U.S. Food and Drug Administration (FDA)...
IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukemia Patients Undergoing Hematopoietic Stem Cell Transplant
December 16, 2021 07:00 ET
|
IN8bio, Inc
The ongoing Phase 1 trial of INB-100 is the first and most clinically advanced program administering large systemic doses of allogeneic gamma-delta T cells to patients 3 patients have been treated to...